Neuren Pharmaceuticals Limited NURPF
13.76 USD 0.00 (+0.00%)
Regular-session close
14.00 Day range 14.00
7.70 52-week range 17.25
- YTD
- +6.58%
- 1 year
- +12.33%
Included in Essentials and up
Sign in to see Fair value
Discounted cash flow estimates against the price, and the P/E against its industry and sector.
Included in Essentials and up
Sign in to see Head count and owner earnings
Employees by annual report and the cash the business earns for its owners.
Included in Essentials and up
Sign in to see P/E against peers
The price to earnings ratio beside the closest competitors and their median.
Included in Essentials and up
Sign in to see Cash flow and returns
How profit turns into free cash flow, and the returns on equity, assets and capital.
Financial health
Altman Z-Score
213.13 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
6 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C+2 / 5 overall
- DCF 2
- Return on Equity 3
- Return on Assets 4
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E 80.6×
P/S 38.4×
P/B 7.3×
P/FCF 19.8×
EV/EBITDA 112×
EV/Sales 38.3×
FCF Yield 5.1%
Profitability
Gross Margin 100.0%
Operating Margin 34.1%
Net Margin 47.1%
ROE 9.0%
ROIC 5.1%
ROA 8.9%
Growth (YoY)
Revenue -70.2%
Operating Income -84.9%
EPS (diluted) -78.0%
Free Cash Flow 1211.1%
Financial Health
Current Ratio 76.6×
Quick Ratio 76.6×
Debt / Equity 0.0×
Net Debt / EBITDA -0.2×
Interest Coverage 0.0×
Dividends
Dividend Yield 0.0%
Payout Ratio 0.0%
Annual · latest fiscal year ends 2025-12-31
